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Abstract 
Aims. Lactate is produced by anaerobic metabolism and may reflect inadequate tissue 
perfusion in conditions such as acute heart failure (AHF). We evaluated the prevalence and 
clinical significance of elevated blood lactate on admission in patients with AHF.  
 
Methods and Results. We enrolled 237 patients with AHF (mean age 67±12 years; 70% 
men) presenting without overt clinical evidence of peripheral hypoperfusion  (“warm 
hemodynamic profile”). Median blood lactate on admission was 1.8 [1.5, 2.4] mmol/L; 103 
(43%) patients had an elevated blood lactate (≥2 mmol/l). Patients with an elevated lactate 
had higher blood high-sensitivity troponin I (15.4 [8.5; 26.1] vs 9.9 [4.3; 19.6] pg/mL, 
aspartate aminotransferase (28 [20; 44] vs 24 [19; 36] IU/L) and endothelin-1  (12.1±6.2 vs 
9.3±3.9 pg/mL), (all p<0.05). In this group plasma concentration of neutrophil gelatinase-
associated lipocalin increased during the first 48 hours, whereas values fell for those with 
normal baseline lactate: 1.9 [-3.2; 9.7] vs -1.3 [-13.9; 5.6] µg/dL (p<0.05). One-year mortality 
was higher amongst patients with an elevated blood lactate (36% versus 21%; p<0.05). After 
adjustment for other well-established prognostic variables, blood lactate on admission 
predicted poor outcome: hazard ratio (95% confidence interval): 1.24 (1.08-1.4) (p<0.05).  
 
Conclusions. An elevated blood lactate on admission is common in AHF patients without 
overt clinical evidence of peripheral hypoperfusion and is associated with markers of organ 
dysfunction/damage and a worse prognosis. 
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Introduction 
Traditionally, lactate is considered an end-product of anaerobic cell metabolism, signalling 
tissue hypoxia, most often due to impaired peripheral perfusion 1. However, an interpretation 
of systemic lactate level is far more complex and reflects tuned balance between lactate 
production and elimination1. Under normal conditions, the former occurs in most tissues, 
mainly in the skeletal muscle, whereas lactate is rapidly cleared predominantly in the liver and 
the kidneys1–3. Both processes – lactate production and elimination – can be affected by 
numerous factors, like tissue energy requirement, peripheral perfusion, adrenergic activity, 
hormones, use of concomitant medications and liver blood flow/function 1–3. 
In critical care medicine, increased blood lactate is a marker of tissue hypoperfusion, being a 
powerful prognostic marker, and is often used in the therapeutic decision-making algorithms 
4–6. Interestingly, only few studies have reported on blood lactate in heart failure, either 
chronic or acute 7,8. In the settings of acute heart failure (AHF) there are several mechanisms 
which can potentially alter a production/clearance balance, promoting lactate accumulation, 
namely: peripheral hypoperfusion (due to low cardiac output, high central venous pressure or 
vasoconstriction), activation of sympathetic drive, hypoxaemia, anaemia, liver or renal 
dysfunction3. Some of these mechanisms may conspire to impair oxygen delivery to 
peripheral organs and accelerate disease progression and worsen prognosis. Therefore, an 
early (baseline) assessment of lactate in AHF patients may be important to identify imperilled 
patients and for implementation of more adequate treatment strategies to improve the outcome 
in AHF. 
Accordingly, we aimed to describe the prevalence, clinical characteristics and consequences 
of an elevated blood lactate amongst patients with AHF without overt clinical evidence of 
hypoperfusion.  
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Methods 
Study population 
The study population consists of patients who were hospitalized at the Centre of Heart 
Diseases, 4th Military Hospital, Wroclaw, Poland, and prospectively included into two AHF 
registries that run in our institution between either 2009-2010 or 2010-2012 9,10. The detailed 
flowchart of the study population has been presented in the supplementary section (Figure 
S1). Inclusion criteria for this analysis were: age ≥18 years; AHF as the primary cause of 
hospitalization AHF (diagnosis was based on the European Society of Cardiology [ESC] 
guidelines criteria 11,12; patient’s written agreement to participate. Exclusion criteria included 
cardiogenic shock or clinically obvious hypoperfusion (clinical assessment was either 
performed or supervised by a cardiologist experienced in heart failure management); a clinical 
diagnosis of concurrent acute coronary syndrome or infection; known severe liver disease or 
renal disease requiring or with planned renal replacement therapy. After inclusion, 
information on demographics, clinical history, comorbidities, previous therapies and physical 
findings was recorded. The present analysis is retrospective and includes only patients in 
whom lactates were measured on admission as a part of standard blood test to assess capillary 
blood oxygen saturation and acid-base balance. For the purposes of this analysis, an elevated 
blood lactate was defined as ≥ 2 mmol/l 13–15.  
 
Patients were treated in accordance with the attending physicians’ recommendations of the 
ESC guidelines 11,12 rather than by a protocol. The research was approved by the local ethics 
committee, and all subjects gave written informed consent. The study was conducted in 
accordance with the Declaration of Helsinki. 
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Laboratory measurements 
On admission (blood samples were drawn at the Emergency Department as a part of a 
standard AHF patient care), the following laboratory measurements were recorded using 
standard methods:  
• capillary blood for oxygen saturation, carbon dioxide concentration, pH, bicarbonate 
and lactate (direct method, ABL 800 Flex analyzer, Radiometer Copenhagen) 
• hematology: hemoglobin (HGB), leukocytes (WBC), platelets 
• serum electrolytes: sodium (Na+), potassium (K+) 
• renal and liver function tests: creatinine; estimated glomerular filtration rate [eGFR] 
16, blood urea nitrogen (BUN), AST (Aspartate aminotransferase), ALT (Alanine 
Aminotransferase), bilirubin and albumin. 
• plasma NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) (method: 
immunoenzymatic, Siemens, Marburg, Germany) 
 
For patients who were enrolled between 2010-2012, we also measured additional biomarkers 
from venous blood samples taken at admission and 24 and 48 hours afterwards:  
• NGAL (Neutrophil gelatinase-associated lipocalin), and high-sensitive troponin I (hs-
TnI) reflecting renal and myocardial damage; 
• Endothelin-1 – as highly potent endogenous vasoconstrictor 
After centrifugation, supernatant plasma was immediately frozen at -70°C until assayed. The 
analysis of these biomarkers was based on a diagnostic platform (Singulex, Inc. (Alameda, 
CA, USA with the Erenna immunoassay system, which uses a microparticle immunoassay 
and single molecule counting technique in a capillary flow system 17. 
 
Page 6 of 18 
 
Definitions 
Consistent with established definitions of myocardial injury, hs-TnI concentration was 
defined as elevated when its value exceeded the 99th percentile of the upper reference limit 
for the assay i.e. 10.19 ng/L 17. A significant increase in hs-TnI was defined as at least one hs-
TnI value (at 24 or 48 hours) >20% above baseline 18. Worsening renal function was defined 
as an increase in plasma creatinine ≥ 0.3 mg/l above baseline 19. For creatinine, NGAL and 
hsTnI, peak levels were defined as the maximum value at any time within the first 48 hours. 
Peak change was the largest difference in log2-transferred values between baseline and 48 
hours. 
Clinical follow-up 
Surviving patients were followed at the heart failure clinic for at least twelve months. 
Information was obtained directly from patients or their relatives (telephone contact), from the 
heart failure clinic database or from the hospital system. No patient was lost to follow-up.  
The primary end-point of interest was all-cause mortality at one year.  
Statistical Analysis  
Continuous variables with a normal distribution were described using means ± standard 
deviation, variables with skewed distribution were described by medians with upper and 
lower quartiles, categorized variables were given as numbers and percentages. The statistical 
significance of differences between the groups were assessed using: t-test, Mann-Whitney U-
test or Chi2 test, where appropriate. The associations between clinical/laboratory variables and 
lactate level on admission were assessed by Spearman correlation test, then the multivariable 
regression models were built. The Cox proportional hazards model was used to calculate the 
hazard ratio (HR) with corresponding 95% confidence interval (95% CI) for all-cause 
mortality. Proportional hazards assumption was verified by visual analisis of Martingale 
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residuals. Kaplan-Meier survival curves were constructed to demonstrate the survival. The p 
<0.05 was considered statistically significant. Statistical analyses were performed using the 
STATISTICA 12 (StatSoft, Inc, Tulsa, OK. 74104, USA).  
 
Results 
Characteristics of the population (Tables 1 and 2) 
Of 237 patients enrolled, most had decompensated chronic heart failure (78%), were men 167 
[70%]  with ischemic heart disease (55%), and mean age of 67±12 years. Mean systolic blood 
pressure, haemoglobin and serum creatinine on admission were: 134±32 mmHg, 13±1.9 g/dl 
and 1.3±0.6 mg/dl, respectively. The median (upper and lower quartiles) plasma  
concentration of NTproBNP was grossly elevated at 5773 [2984, 10382] pg/ml.  
The distribution of lactate levels is presented in Figure 1. Median (upper and lower quartiles) 
blood lactate on admission was 1.8 [1.5, 2.4] mmol/L and 103 (43%) patients had elevated 
lactate concentrations (≥ 2mmol/L).  The characteristics of patients with lactate above or 
below 2mmol/L were broadly similar (Table 1). Patients with lactates ≥ 2 mmol/L had faster 
heart rate and higher diastolic blood pressure (94±26 vs 89±24 beats/min and 80±20 vs 73±21 
mmHg, respectively, p<0.01 in both comparisons). Patients with elevated lactate levels also 
had higher baseline values of WBC (9.8±3.8 vs 8.6±3.4 x103/µL), platelets (236±106 vs 
209±76 x103/µL), and lower pH (7.41 vs 7.43) and HCO3- (22 vs 25 mmol/l) vs those with 
normal lactates (all p< 0.05).  
Table 2 summarizes the results of the analyses to identifying predictors of lactate level on 
admission. In the multivariable models heart rate, WBC, AST, ALT and ET-1 were 
independent predictors of lactate level. 
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Elevated lactates level and biomarkers of organ dysfunction/injury (Table 3) 
Liver  
Patients with elevated lactate levels on admission had higher values of AST (28 [20; 44] vs 24 
[19; 36] IU/L, p=0.02) and a trend towards higher values of ALT (26 [18; 47] vs 24 [17; 35] 
IU/L; p=0.07) (medians with upper and lower quartiles, respectively). Values for bilirubin and 
albumin on admission were similar between groups. 
Kidney   
Patients with blood lactate above or below 2.0 mmol/L had similar serum creatinine 
concentrations at baseline and 48h: (1.3±0.6 vs 1.4±0.6 and 1.2±0.6 vs 1.3±0.6 mg/dL, 
respectively) and similar rates of worsening renal function during the first 48 hours (4% vs 
8%) (all p>0.05). Plasma concentrations of NGAL on admission were lower amongst those 
with elevated lactate (29.3±16.2 vs 42.7±30.5 µg/dl, p<0.01), but increased during the first 48 
hours, whereas values fell for those with normal baseline lactate: 1.9 [-3.2; 9.7] vs -1.3 [-13.9; 
5.6] µg/dl (p<0.05).      
Myocardium 
Patients with and without an elevated lactate on admission had similar baseline plasma 
concentrations of hs-TnI. Peak hs-TnI and hs-TnI measured at 48h were higher in patients 
with elevated lactate: 19.8 [10.4; 49.4] vs 14.5 [6.9; 28.2] and 15.4 [8.5; 26.1] vs 9.9 [4.3; 
19.6] pg/ml, respectively (both p<0.05).  
Vasoconstriction  
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 Patients with elevated lactate had higher concentration of endothelin-1 on admission 
(12.1±6.2 vs 9.3±3.9 pg/mL, p<0.01), with subsequent significant decrease within 48h (-1.9 [-
4.8;-0.6] vs -0.2 [-1.3;0.7], p<0.001). 
   
Peripheral blood lactates and mortality 
Sixty five patients (27%) died in the first year; 36% of those with a blood lactate ≥2mmol/l 
and 21% with lower values (p<0.05) (Figure 2). On univariate analysis elevated blood lactate 
on admission predicted all-cause mortality HR (95% CI): 1.2 (1.02-1.4) (p<0.05). After 
adjusting for well-established prognostic markers (age, systolic blood pressure, hemoglobin, 
creatinine, serum sodium, NTproBNP levels), the association between elevated blood lactate 
on admission and one-year, all-cause mortality was strengthened HR(95% CI): 2.7 (1.6-4.5) 
(p<0.001) (Table 4). Additional mortality analyses are resented in supplementary materials. 
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Discussion 
We found that blood lactate was commonly elevated at admission amongst patients with 
AHF, even if clinical evidence of hypoperfusion was not obvious, and was associated with 
increases in biomarkers reflecting dysfunction or damage to the liver, myocardium, the 
kidney, vasoconstriction, and, ultimately, a higher mortality rate.  
Several reports have confirmed the prognostic utility of blood lactate concentrations in critical 
care populations, including patients with septic shock, after cardiac arrest or multiple trauma 
4–6,14. However, there are few data available for patients with heart failure 7,8,20. A previous 
study of just 27 patients with decompensated chronic heart failure found that >80% had an 
elevated blood lactate and that this was associated with low mixed venous oxygen saturations 
without marked arterial oxygen desaturation suggesting hypoperfusion as the main contributor 
to raised lactate 7. These authors noted the poor relationship between raised lactate and vital 
signs but did not investigate the relationship with prognosis. Additionally, these patients were 
clinically far different from our population, and represented advanced, late stage of the 
disease, with lower blood pressure, severely compromised left ventricular ejection fraction, 
more than 80% receiving inotropic support. Adamo et al 8, reported prevalence of elevated 
lactate lower than our study, but they studied stable patients, who despite having an advanced 
disease may have already adapted mechanisms for a higher lactate clearance. In patients with 
cardiogenic shock elevated lactate (>2mmol/l) predicted poor outcome 20, being also the 
variable used in the CardShock risk Score to stratify risk of short-term mortality in this 
population 20.         
Patients with or without an elevated blood lactate were similar in terms of demographic, 
clinical or laboratory variables and, although prognosis was markedly different, they had very 
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similar indices of disease severity, suggesting that lactate is a biomarker independent from 
most other clinical variables. Lactate level in the blood reflects a balance between production 
and clearance, which in the settings of AHF can be impaired, favouring lactate accumulation3. 
Although our study was not designed to elucidate such underlying mechanisms, it is worthy to 
note that the multivariable analysis revealed HR, WBC, AST, ALT and ET-1 as independent 
predictors of elevated lactate level. Both elevated HR and WBC may be indirect markers of 
sympathetic overactivity in these patients, but an increase in leukocytes may be also a 
physiological response to metabolic acidosis. As C-reactive protein was similar whether or 
not lactate was elevated, we believe higher WBC counts did not appear linked to infection. 
Additionally, although we excluded patients with known severe renal and kidney dysfunction, 
a relationship with higher AST/ALT levels may indicate that impaired liver function (and 
hepatic lactates clearance) potentially also contributes. In our study, patients with elevated 
blood lactate demonstrated higher levels of endothelin-1, providing an indirect evidence of 
more pronounced endothelin-mediated vasoconstriction at the periphery21. High systemic 
vascular resistance, regulated by microvascular tone, may maintain blood pressure when 
cardiac output is low and therefore a normal or even raised blood pressure cannot be equated 
with adequate tissue perfusion. Therefore, even in AHF patients with “warm profile” on 
clinical examination, peripheral hypoperfusion may be another factor responsible for elevated 
lactates. 
 
We have found biomarker evidence of organ (liver, cardiac and perhaps renal) injury within 
the first 48h of hospitalization in patients with a high blood lactate. This could reflect 
hypoxia, congestion or a combination of the two, all of which may lead to organ dysfunction 
in AHF 9,18,22,23. Organ perfusion depends on the net difference between arterial and venous 
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pressure and arteriolar tone. High venous tone will not only cause organ congestion but also a 
fall in net perfusion pressure and therefore exacerbate hypoxia 24. Congestion and 
hypoperfusion may often co-exist and improvement in one may improve the other. On the 
other hand, endothelin-mediated peripheral vasoconstriction, present in patients with a high 
blood lactate, may also indicate inadequate perfusion leading to organ injury, as discussed 
above. Interestingly, similarly to intensive care populations, we have shown that elevated 
blood lactate on admission is associated with high mortality also in AHF patients without  
overt clinical evidence of peripheral hypoperfusion (who are not considered as candidates for 
an intensive care). Poor outcome in these patients may be a result of organ 
damage/dysfunction due to inadequate peripheral perfusion (otherwise clinically concealed) 
and may reflect more profound hemodynamic/neurohormonal abnormalities. This goes 
together with an observation of elevated endothelin-1 in these patients. It has been recently 
reported that elevated endothelin-1 on admission is an independent predictor of short-term in-
hospital outcomes and 180-day mortality in patients with AHF 21.          
There are several limitations to this report. Patient numbers, especially for the biomarker 
analysis, were small and the analyses were retrospective. As the study comprised AHF 
patients without severe haemodynamic compromise, and the lactate levels were lower than in 
intensive care populations, the results can’t be extrapolated to a broader range of lactate 
levels. In our study lactates were measured from capillary blood samples. Although recently 
published data show good correlation between lactate level measured from capillary and 
arterial probes, capillary blood tends to reveal higher values 25,26. However, these studies 
recruited mainly patients in shock with severe microperfusion alterations which we believe 
was not a case in our population.We lack information on dynamic changes in blood lactate 
Page 13 of 18 
 
during hospitalization, which could be a useful marker of the response to therapeutic 
interventions.  
In summary, elevated blood lactate, an indicator of anaerobic metabolism which is most likely 
driven by hypoperfusion of essential organs is common in AHF and carries independent 
prognostic information. Blood lactate concentration may be useful for risk stratification, but 
whether this would be incremental to the already validated models is not known. Further 
research is required to demonstrate whether it is useful for monitoring the response to 
intervention or whether it should inform therapeutic decisions. Many clinicians may feel 
instinctively that they should intervene with inotropic or vasodilator agents or even 
mechanical support when blood lactate is elevated but opinions on what to do will vary and 
should be supported by evidence. 
 
Figure 1.  
The distribution of lactates in the AHF population (n=237). 
 
Figure 2.  
Comparison of one-year mortality in 237 AHF patients with peripheral blood lactate on 
admission < 2mmol/l (red line) and ≥ 2mmol/l (blue line).   
                                  log rank  p= 0.02 
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